MedTrace Logo

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

NCT05569512 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-08-19

No results posted yet for this study

Summary

This research study is studying a new drug, uproleselan, to see if it is safe and effective in decreasing relapse after stem cell transplant and improving leukemia-free survival in pediatric patients with acute myeloid leukemia (AML).

The name of the study drugs involved in this study are:

* Uproleselan
* Busulfan
* Clofarabine
* Fludarabine
* Tacrolimus
* Methotrexate
* Mycophenolate Mofetil

Conditions

Interventions

DRUG

Uproleselan

Administered by intravenous infusion

DRUG

Fludarabine

Administered by intravenous infusion

DRUG

Clofarabine

Administered by intravenous infusion

DRUG

Busulfan

Administered by intravenous infusion

Sponsors & Collaborators

  • GlycoMimetics Incorporated

    collaborator INDUSTRY

  • Malika Kapadia

    lead OTHER

Principal Investigators

  • Malika Kapadia, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Months
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2023-10-05
Completion
2023-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05569512 on ClinicalTrials.gov